ESTRO 2023 - Abstract Book

S1145

Digital Posters

ESTRO 2023

No differences were found between the pre- and post-surgical classification based on histology or grade, but statistically significant differences were found in the patients who presented ILV (p=0.049). When analyzing the sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (PPN) of the pre surgical MRI by stages, we found that in IA it was 55.12%, 72.65%, 55.12% and 72.65%, respectively. In stage IB it was 67.05%, 64.46%, 57% and 73.58%. In stage II 11.11%, 94.68%, 16.6% and 91.7%. In FIGO III stage it was 33.3%, 97.25%, 61.53% and 91.7%. In FIGO stage IV, both sensitivity and PPV were 0% and both specificity and PPN were 98.5%. Conclusion MRI in our center plays an important role in excluding patients who do not have cervical stromal invasion as well as extrauterine infiltration or lymph node metastases, but it is necessary to improve in determining the depth of myometrial invasion. M. Miszczyk 1 , E. Staniewska 1 , K. Grudzie ń 2 , K. Raczek-Zwierzycka 1 , J. Rembak-Szynkiewicz 3 , A. d’Amico 4 , D. Borys 4 , Z. Nowicka 5 , M. Sobczak 5 , K. P ł oszka 5 , M. Stankiewicz 6 , R. Tarnawski 1 1 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland, IIIrd Department of Radiotherapy and Chemotherapy, Gliwice, Poland; 2 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland, Radiotherapy Department, Gliwice, Poland; 3 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland, Radiology and Diagnostic Imaging Department, Gliwice, Poland; 4 Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland, Gliwice, Poland; 5 Medical University of Lodz, Poland, Department of Biostatistics and Translational Medicine, Ł ód ź , Poland; 6 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland, Brachytherapy Department, Gliwice, Poland Purpose or Objective To assess the correlation between pretreatment Squamous Cell Carcinoma Antigen (SCCA) and Total Lesion Glycolysis (TLG30) on pretreatment Positron Emission Tomography – Computed Tomography (PET-CT), and to assess the prognostic value of SCCA and TLG30 for survival in patients treated with (chemo)radiotherapy for primary localized cervical cancer. Materials and Methods This retrospective study included all consecutive cervical cancer patients treated with radical intent at one tertiary institution between 2011 and 2017. Metabolic parameters of the tumour were calculated using MIM Software by standardized method and comprised of standardized uptake value (SUVmax30, SUVmin30, SUVmedian30, SUVmean30, SUVvariance30), metabolic tumour volume (MTV30) and TLG30. Spearman's rank correlation coefficient and Cox proportional hazards regression model were used for the analysis to assess the correlation between pretreatment SCCA and TLG30, and to assess the prognostic value of analyzed parameters. Results The final study group consisted of 198 consecutive cervical cancer patients treated with radical intent between 2011 and 2017, with a median age of 57.2 (IQR 48.6-63.2) and median census-based follow-up of 75.8 months (IQR 39.8-104.1). The patients received a combination of external beam radiotherapy (198, 100%), brachytherapy (196, 99%) and concurrent chemotherapy (181, 91%). The 5-year overall survival was 69.2%, and 60.6% of patients were alive at the time of the analysis. Squamous cell carcinoma antigen (SCCA) expression in serum was significantly associated with TLG30 (R=0.463, p<0.001) (Figure 1). In univariate analysis, SCCA expression increase of 1 ng/ml was associated with HR 1.003 (95% CI 1.001-1.006) for overall survival (p=0.024). However, in multivariate analysis including patient age, tumour histology, FIGO stage, ECOG, haemoglobin concentrations and metabolic parameters from PET (TLG30 and SUVmedian30), the association of SCCA expression with patient survival was not significant (p=0.585). PO-1417 The association between PET-CT metabolic parameters, SCCA and survival in cervical cancer patients.